
Donna Ryan
Articles
-
Dec 10, 2024 |
patientcareonline.com | Donna Ryan |Sydney Jennings
December 10, 2024By Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine. Several groundbreaking clinical trials in obesity medicine were published in 2024. Which ones stood out? That is a question Patient Care Online asked Donna Ryan, MD, professor emerita at Pennington Biomedical Research Center in Baton Rouge, LA, and past president of The Obesity Society.
-
Nov 4, 2024 |
healio.com | Scott Buzby |Erik Swain |Donna Ryan |Robert F. Kushner
You've successfully added Obesity in Endocrinology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: SELECT cemented weight pharmacotherapy as a path for CV risk reduction.
-
Jul 1, 2024 |
digitalcommons.library.tmc.edu | Donna Ryan |Ildiko Lingvay |John Deanfield |Steven Kahn
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years.
-
May 29, 2024 |
radcliffecardiology.com | Harold Bays |Sven Francque |Donna Ryan |Naveed Sattar
Video Published: Views: 34 Likes: 0 Average (ratings) ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk). This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes.
-
May 29, 2024 |
radcliffecardiology.com | Harold Bays |Sven Francque |Barbara McGowan |Donna Ryan
Video Published: Views: 31 Likes: 0 Average (ratings) ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA. Questions1. What is the background of this combinatory approach? 2. What data did you present at ERA 24? 3. What are the challenges and opportunities in approaching combinatory treatment? 4.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →